Raymond Pashun, MD
Cardiovascular Disease · Ann Arbor, MINPI 1245659259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,042 of the $2,971 with a category attached, or 68.7%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,073 and has fallen 99.2% since, to $17 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 20 payments — averaging $148.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- AstraZeneca$259
- Boehringer Ingelheim$248
- Pfizer$116
- Getinge USA Sales, LLC$96
- C. R. Bard, Inc. & Subsidiaries$42
- plus $148 from 6 others
What the payments were for
- Speaking & faculty fees$2,04269%
- Food & beverage$92931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $2,061 |
| AstraZeneca | 4 | $259 |
| Boehringer Ingelheim | 2 | $248 |
| Pfizer | 1 | $116 |
| Getinge USA Sales, LLC | 2 | $96 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $42 |
| Boston Scientific | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Abiomed | 1 | $26 |
| Novartis | 1 | $23 |
| Angiodynamics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,971 in reported general payments places this provider in the 50th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Ann Arbor
- Marschall RungeAnn Arbor$1.8M
- Vallerie McLaughlinAnn Arbor$947K
- Stanley ChetcutiAnn Arbor$573K
- David BachAnn Arbor$390K
- Bertram PittAnn Arbor$298K
- Victor MolesAnn Arbor$120K
- Salim HayekAnn Arbor$92K
- Ashwini KerkarAnn Arbor$84K
- Priya MehtaAnn Arbor$70K
- Raymond YeowAnn Arbor$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.